Publications (selected)

2015

• Ahrens HE, Petersen B, Herrmann D, Lucas-Hahn A, Hassel P, Ziegler, M, Kues WA, Baulain U, Baars W, Schwinzer R, Denner J, Rataj D, Werwitzke S, Tiede A, Bongoni AK, Garimella PS, Despont A, Rieben, R, and Niemann H. siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 15, 1407-1414.
  
  
• Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkuhler K, Kalus U, Blumtritt JM, Werwitzke S, Budde E, Koch A, and Knobl P. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 125, 1091-1097.
  
  
• Hofbauer CJ, Whelan SF, Hirschler M, Allacher P, Horling FM, Lawo JP, Oldenburg J, Tiede A, Male C, Windyga J, Greinacher A, Knobl PN, Schrenk G, Koehn J, Scheiflinger F, and Reipert BM. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 125, 1180-1188.
  
  
• Werwitzke S, Vollack N, von Hornung M, Kalippke K, Kutzschbach J, Trummer A, Ganser A, and Tiede A. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. Thrombosis and haemostasis 114, in press.
  
  
• Ramackers W, Klose J, Tiede A, Werwitzke S, Rataj D, Friedrich L, Johanning K, Vondran FW, Bergmann S, Schuettler W, Bockmeyer, CL, Becker JU, Klempnauer J, and Winkler M. Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneys. Xenotransplantation 22, 284-294.

 2014

• Ramackers W, Friedrich L, Klose J, Vondran F, Bergmann S, Schuttler, W, Johanning K, Werwitzke S, Trummer A, Brocker V, Klempnauer J, Winkler M, and Tiede A. Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation. Xenotransplantation 21, 367-375.
  
  
• Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, Koschmieder S, Matzdorff A, Tiede A, Griesshammer M, Riess H. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol in press. PubMed PMID: 25307456.
  
  
• Tiede A, Werwitzke S, Scharf RE. Laboratory Diagnosis of Acquired Hemophilia A: Limitations, Consequences, and Challenges. Semin Thromb Hemost in press. PubMed PMID: 25299927.
  
  
• Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S. The first recombinant FVIII produced in human cells--an update on its clinical development programme. Haemophilia; 20 (Suppl 1): 1-9.
  
  
• Trummer A, Werwitzke S, Wermes C, Ganser A, Birschmann I, Budde, U, and Tiede A. Addition of in-vitro generated endothelial microparticles to von-Willebrand plasma improves primary and secondary hemostasis. Thrombosis research 133, 445-450.

• Fink S E, Gandhi M K, Nourse J P, Keane C, Jones K, Crooks P, Jöhrens K, Korfel A, Schmidt H, Neumann S, Tiede A, Jäger U, Dührsen U, Neuhaus R, Dreyling M, Borchert K, Südhoff T, Riess H, Anagnostopoulos I, Trappe RU. A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors. Am J Transplant in press.

 2013

• Federici A B, Budde U, Castaman G, Rand J H, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013; 39: 191-201.
  
  
• Whelan SF, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, Male C, Windyga J, Tiede A, Schwarz HP, Scheiflinger F, Reipert BM. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 121:1039-48.
  
  
• Heuft HG, Goudeva L, Krauter J, Peest D, Buchholz S, Tiede A. Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation. Vox Sang. 105: 18-27.
  
  
• Tiede A, Brand B, Fischer R, Kavakli K, Lentz S R, Matsushita T, Rea C, Knobe K, Viuff D. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013; 11: 670-8.
  
  
• Trummer A, Haarmeijer B, Werwitzke S, Wermes C, Ganser A, Budde U, Tiede A. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin. Haemophilia. 2013; 19: 236-41.
  
  
• Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, Gürtler L. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica. 98: 1495-8.
  
  
• Lentz S R, Misgav M, Ozelo M, Salek S Z, Veljkovic D, Recht M, Cerqueira M, Tiede A, Brand B, Mancuso M E, Seremetis S, Lindblom A, Martinowitz U. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia; 19: 691-7.

 2012

• Tiede A. Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res. 130 (Suppl 2): 2-6.
  
  
• Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood, 120: 2405-2411.
  
  
• Sørensen B, Dargaud Y, Kenet G, Lusher J, Mumford A, Pipe S, Tiede A. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia; 18: 255-262.
  
  
• Wilhelmi M H, Tiede A, Teebken OE, Bisdas T, Haverich A, Mischke R. Ovine blood: establishment of a list of reference values relevant for blood coagulation in sheep. ASAIO J ; 58: 79-82.
  
  
• Barthels M (Hrsg.) und Mitarbeiter: Das Gerinnungskompendium, 2. Auflage, Stuttgart. Thieme-Verlag. (Autor der Kapitel "Hämophilie A und B", "Erworbene Faktorenmängel", "Vitamin-K-Mangel", "Leberfunktionsstörungen", "Disseminierte intravasale Gerinnung", "Grundlagen der Gerinnungsdiagnostik", "Faktorenkonzentrate")
  
  
• Koscielny J, Beyer-Westendorf J, von Heymann C, Braun J, Klamroth R, Lindhoff-Last E, Tiede A, Spannagl M. Blutungsrisiko und Blutungsnotfälle unter Rivaroxaban. Hämostaseologie; 32: 287-293.

2011

• Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I Treat acquired von Willebrand syndrome. Blood. 117: 6777-6785.
  
  
• Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood, 118: 2695-2701.
  
  
• Tiede A, Friedrich U, Stenmo C, Allen G, Giangrande P, Goudemand J, Hay C, Holmstrom M, Klamroth R, Lethagen S, McKenzie S, Miesbach W, Negrier C, Yuste VJ, Berntorp E. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). J Thromb Haemost, 9: 1191-1199.
  
  
• Petersen B, Ramackers W, Lucas-Hahn A, Lemme E, Hassel P, Queißer A L, Herrmann D, Barg-Kues B, Carnwath J E, Klose J, Tiede A, Friedrich L, Baars W, Schwinzer R, Winkler M, Niemann H. Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. Xenotransplantation, 18: 355-368.
  
  
• Sørensen B, Dargaud Y, Kenet G, Lusher J, Mumford A, Pipe S, Tiede A. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia; 18: 255-62.
  
  
• Martinowitz U, Bjerre J, Brand B, Klamroth R, Misgav M, Morfini M, Santagostino E, Tiede A, Viuff D. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia, 17: 854-59.

2010 

• Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol. 2010, 89: 607-612.
  
  
• Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Ann Hematol., 89: 309-16.

2009

• Tiede A, Huth-Kuhne A, Oldenburg J, Grossmann R, Geisen U, Krause M, Brand B, Alberio L, Klamroth R, Spannagl M, Knobl P. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol, 88: 365-370.
  
  
• Petersen B, Ramackers W, Tiede A, Lucas-Hahn A, Herrmann D, Barg-Kues B, Schuettler W, Friedrich L, Schwinzer R, Winkler M, Niemann H. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation, 16: 486-495.
  
  
• Kalippke K, Werwitzke S, von Hornung M, Mischke R, Ganser A, Tiede A. DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders. Lab Anim; 43: 390-3.
  
  
• Trummer A, De Rop C, Tiede A, Ganser A, Eisert R. Recovery and composition of microparticles after snap-freezing depends on thawing temperature. Blood Coagul Fibrinolysis; 20: 52-6.

 2008

• Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia, 14: 736-742.
  
  
• Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, Eisert R, Ganser A, Budde U. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost, 6: 569-576. Replacement therapy of hemophilia and other disorders of hemostasis.  Active and ongoing participation in international clinical trials in hemophilia A and B, von Willebrand disease, antithrombin deficiency and reversal of oral anticoagulation.
  
  
• Tiede A, Tait RC, Shaffer D W, Baudo F, Boneu B, Dempfle C E, Horellou M H, Klamroth R, Lazarchick J, Mumford AD, Schulman S, Shiach C, Bonfiglio LJ, Frieling JT, Conard J, von Depka M. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost 2008, 99: 616-22.
  
  
• Ramackers W, Friedrich L, Tiede A, Bergmann S, Schuettler W, Schuerholz T, Mengel M, Goudeva L, Ganser A, Klempnauer J, Piepenbrock S, Winkler M. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation. 15: 46-55.
  
  
• Trummer A, De Rop C, Tiede A, Ganser A, Eisert R. Isotype controls in phenotyping and quantification of microparticles: a major source of error and how to evade it. Thromb Res; 122: 691-700.
  
  
• Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, Tiede A, Jacob U, Schmidt R E, Witte T. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). Ann Rheum Dis; 67: 154-61.
  
  
• Werwitzke S, Tiede A, Jacobs R, Zielinska-Skowronek M, Buyny S, Schmidt R E, Witte T. CD8alpha+beta(low) effector T cells in systemic lupus erythematosus. Scand J Immunol; 67: 501-8.

2007

• Tiede A. Perioperatives Gerinnungsmanagement. Chirurg; 78: 69-79.

2003

• Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem H P, Ganser A, Scherr M. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther; 10: 1917-25.
  
  
• Werwitzke S, Tiede A, Drescher B E, Schmidt R E, Witte T. CD8beta/CD28 expression defines functionally distinct populations of peripheral blood T lymphocytes. Clin Exp Immunol; 133: 334-43.

2002

• Tiede A. Hämophilie A und B. In: von Depka Prondzinski (Hrsg.) Blutgerinnung - aktuelle Aspekte der Physiologie, Pathophysiologie, Klinik, Diagnostik, Prophylaxe und Therapie. Bremen: Uni-Med.

2001

• Tiede A, Daniels RJ, Higgs DR, Mehrein Y, Schmidt RE, Schubert J. The human GPI1 gene is required for efficient glycosylphosphatidylinositol biosynthesis. Gene; 271: 247-54.

2000

• Tiede A, Nischan C, Schubert J, Schmidt RE. Characterisation of the enzymatic complex for the first step in glycosylphosphatidylinositol biosynthesis. Int J Biochem Cell Biol; 32: 339-50.
  
  
• Bastisch I, Tiede A, Deckert M, Ziolek A, Schmidt RE, Schubert J. Glycosylphosphatidylinositol (GPI)-deficient Jurkat T cells as a model to study functions of GPI-anchored proteins. Clin Exp Immunol; 122: 49-54.

1999

• Tiede A, Bastisch I, Schubert J, Orlean P, Schmidt R E. Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes. Biol Chem; 380: 503-23.

1998

• Tiede A, Schubert J, Nischan C, Jensen I, Westfall B, Taron CH, Orlean P, Schmidt RE. Human and mouse Gpi1p homologues restore glycosylphosphatidylinositol membrane anchor biosynthesis in yeast mutants. Biochem J; 334: 609-16.